ArticleInternational journal of clinical and experimental pathology2015
Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assessment of biochemical recurrence of prostate cancer (Review).International journal of oncology · 2019Pooled it
- The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.Journal of cellular biochemistry · 2018Pooled it
- MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring.Cells · 2026Review
- Hypoxia-Mediated Downregulation of Exosomal miR-128-3p Promotes Lymphangiogenesis via VEGF-C in Oral Squamous Cell Carcinoma.International journal of dentistry · 2026Article
- miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.Medical oncology (Northwood, London, England) · 2025Review
- miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.Medical oncology (Northwood, London, England) · 2025Review
- miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.Medical oncology (Northwood, London, England) · 2025Review
- MicroRNA-128 acts as a suppressor in the progression of gastrointestinal stromal tumor by targeting B-lymphoma Mo-MLV insertion region 1.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms.Cancers · 2023Review
- MiR-128 suppresses metastatic capacity by targeting metadherin in breast cancer cells.Biological research · 2020Article
- Identification and analysis of survival-associated ceRNA triplets in prostate adenocarcinoma.Oncology letters · 2019Article
- MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1.Oncology letters · 2018Article
- Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1.Oncology letters · 2018Article
- Down-regulated serum miR-126 is associated with aggressive progression and poor prognosis of gastric cancer.Cancer biomarkers : section A of Disease markers · 2018Article
- Role of MicroRNAs in Treatment Response in Prostate Cancer.Current cancer drug targets · 2018Review
- Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?International journal of molecular sciences · 2017Review
- The SNAIL/miR-128 axis regulated growth, invasion, metastasis, and epithelial-to-mesenchymal transition of gastric cancer.Oncotarget · 2017Article
- The translational potential of microRNAs as biofluid markers of urological tumours.Nature reviews. Urology · 2016Review
- miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer.Translational oncology · 2016Article
- Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeMicroRNA-128 (miR-128) has been identified as a negative regulator of malignant phenotypes of prostate cancer (PCa) cells. The aim of this study was to evaluate the prognostic implications of both tissue and serum levels of miR-128 expression in PCa patients undergoing radical prostatectomy.
methodsA series of 128 cases with PCa were evaluated for both tissue and serum levels of miR-128 expression by quantitative reverse-transcription PCR.
resultsCompared with non-cancerous prostate tissues and normal sera, both tissue and serum levels of miR-128 expression were significantly decreased in PCa patients (both P<0.001). Importantly, there was a close correlation between tissue and serum levels of miR-128 expression in PCa patients (rs=0.808, P<0.001). Then, low miR-128 expression in both PCa tissues and patients' sera were dramatically associated with aggressive clinicopathological features, including advanced pathological stage (both P=0.001), positive lymph node metastasis (P=0.006 and 0.01, respectively), high preoperative PSA (both P=0.01) and positive angiolymphatic invasion (both P=0.02). Moreover, Kaplan-Meier survival analysis showed that low miR-128 expression in both PCa tissues and patients' sera were significantly associated with short biochemical recurrence (BCR)-free survival. Furthermore, multivariate analysis indicated that both tissue and serum levels of miR-128 expression were independent prognostic factors for BCR-free survival of PCa patients.
conclusionOur data suggest that the decreased expression of miR-128 in both tissue and serum samples of PCa patients may be associated with tumor malignant progression and BCR-free survival. Particularly, serum miR-128 may be developed as a novel noninvasive biomarker for PCa diagnosis and prognosis.
Indexed as
Identifiers
26339409PMC4555737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.